TY - JOUR
T1 - Growth kinetics of small cell carcinoma of the lung
AU - Lenhard, Raymond E.
AU - Woo, Kwang B.
AU - Freund, Johns S.
AU - Abeloff, Martin D.
N1 - Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1981/8
Y1 - 1981/8
N2 - Tumor volumes prior to initial therapy for 33 patients with small cell carcinoma of the lung were determined from serially measurable roentgenographic lesions. Tumor doubling times were calculated for 20 patients who had two or more serial measurements. Pretreatment tumor volumes ranged from <5 to 485 cm3, with a median of 87 cm3, a log mean of 61 cm3, and an arithmetic mean of 103 cm3. The tumor doubling times (DT) ranged between 12 and 209 days, with a median of 53 days, a log mean of 59 days, and an arithmetic mean of 79 days. The tumor growth rate, expressed by tumor doubling time, was correlated with the tumor volume (r = -0.533, P < 0.05); and volume dependency of the tumor growth rate, as specified in Gompertzian growth, was demonstrated. Patients with DT < 79 days had a median duration of survival of 15 months, which was significantly longer (P = 0.046) than the median survival of 8 months for patients with DT > 79 days.
AB - Tumor volumes prior to initial therapy for 33 patients with small cell carcinoma of the lung were determined from serially measurable roentgenographic lesions. Tumor doubling times were calculated for 20 patients who had two or more serial measurements. Pretreatment tumor volumes ranged from <5 to 485 cm3, with a median of 87 cm3, a log mean of 61 cm3, and an arithmetic mean of 103 cm3. The tumor doubling times (DT) ranged between 12 and 209 days, with a median of 53 days, a log mean of 59 days, and an arithmetic mean of 79 days. The tumor growth rate, expressed by tumor doubling time, was correlated with the tumor volume (r = -0.533, P < 0.05); and volume dependency of the tumor growth rate, as specified in Gompertzian growth, was demonstrated. Patients with DT < 79 days had a median duration of survival of 15 months, which was significantly longer (P = 0.046) than the median survival of 8 months for patients with DT > 79 days.
UR - http://www.scopus.com/inward/record.url?scp=0019518491&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019518491&partnerID=8YFLogxK
U2 - 10.1016/0014-2964(81)90312-1
DO - 10.1016/0014-2964(81)90312-1
M3 - Article
C2 - 6276183
AN - SCOPUS:0019518491
SN - 0014-2964
VL - 17
SP - 899
EP - 904
JO - European Journal of Cancer (1965)
JF - European Journal of Cancer (1965)
IS - 8
ER -